BRAF and cancer: We first tested the combined down-regulation of endogenous BRAF with exogenous complementation by a BRAF V600E cancer mutation using a Donor D2.4 variant (pMDS-GOI-TETon- tTS) in HEK293 cells grown in serum-containing medium.